Antibodies Responses to SARS-CoV-2 in a Large Cohort of Vaccinated Subjects and Seropositive Patients.
Antibodies Responses to SARS-CoV-2 in a Large Cohort of Vaccinated Subjects and Seropositive Patients.
复制标题
DOI：
10.3390/vaccines9070714
复制
发表时间：
2021-07-01
期刊：
影响因子：
7.8
通讯作者：
Bonura F
中科院分区：
文献类型：
--
作者：
Amodio E;Capra G;Casuccio A;Grazia S;Genovese D;Pizzo S;Calamusa G;Ferraro D;Giammanco GM;Vitale F;Bonura F
COVID-19是当前的全球威胁，抗体反应的表征对于更新疫苗开发和策略至关重要。在这项研究中，我们评估了SARS-CoV-2阳性患者（N = 272）和接种BNT 162 b2 m-RNA COVID-19疫苗的受试者（N = 1256）中的SARS-CoV-2抗体浓度。对于每个参与者，收集了社会人口统计学数据，COVID-19疫苗接种记录，血清学分析和SARS-CoV-2感染状况。检测SARS-CoV-2 S1/S2抗原的IgG抗体。几乎所有接种疫苗的受试者（99.8%）显示抗SARS-COV-2 IgG的血清阳性，并且超过80%的接种疫苗的受试者具有> 200 Au/mL的IgG浓度。在Tobit多变量回归分析中，SARS-CoV-2疫苗接种与IgG浓度增加具有统计学显著相关性（β系数= 266.4; p < 0.001）。SARS-CoV-2 IgG浓度随着年龄的增长（β系数=每年增加-1.96; p < 0.001）、男性（β系数=-22.3; p < 0.001）和免疫后天数（β系数=每天增加-1.67; p < 0.001）而显著降低。我们的研究结果可以支持疫苗接种活动，证实正在调查的SARS-CoV-2疫苗对自然感染的高免疫原性。需要进一步研究，以评估年龄和免疫后天数在疫苗抗体持续存在和预防疾病方面的作用。
COVID-19 is a current global threat, and the characterization of antibody response is vitally important to update vaccine development and strategies. In this study we assessed SARS-CoV-2 antibody concentrations in SARS-CoV-2 positive patients (N = 272) and subjects vaccinated with the BNT162b2 m-RNA COVID-19 vaccine (N = 1256). For each participant, socio-demographic data, COVID-19 vaccination records, serological analyses, and SARS-CoV-2 infection status were collected. IgG antibodies against S1/S2 antigens of SARS-CoV-2 were detected. Almost all vaccinated subjects (99.8%) showed a seropositivity to anti-SARS-COV-2 IgG and more than 80% of vaccinated subjects had IgG concentrations > 200 AU/mL. In a Tobit multivariable regression analysis, SARS-CoV-2 vaccination was statistically significantly associated with increased IgG concentrations (β coef = 266.4; p < 0.001). A statistically significant reduction in SARS-CoV-2 IgG concentrations was found with older age (β coef = −1.96 per year increase; p < 0.001), male sex (β coef = −22.3; p < 0.001), and days after immunization (β coef = −1.67 per day increase; p < 0.001). Our findings could support the vaccination campaigns confirming the high immunogenicity of the SARS-CoV-2 vaccine under investigation with respect to the natural infection. Further studies will be required for evaluating the role of age and days after immunization in the persistence of vaccine antibodies and protection from the disease.